You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for In RE: Point Blank Solutions Inc. (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


In RE: Point Blank Solutions Inc. (D. Del. 2022)

Docket 1:11-cv-00505 Date Filed 2022-02-11
Court District Court, D. Delaware Date Terminated 2022-05-19
Cause 35:271 Patent Infringement Assigned To
Jury Demand None Referred To
Patents RE41,783
Link to Docket External link to docket
Small Molecule Drugs cited in In RE: Point Blank Solutions Inc.
The small molecule drugs covered by the patent cited in this case are ⤷  Get Started Free and ⤷  Get Started Free .

Litigation Summary and Analysis for In RE: Point Blank Solutions Inc. (1:11-cv-00505)

Last updated: March 1, 2026

What Are the Core Litigation Issues?

The case In RE: Point Blank Solutions Inc. (1:11-cv-00505) involves securities class action allegations against Point Blank Solutions Inc., a manufacturer of body armor. The plaintiffs allege securities fraud related to misstatements and omissions in financial disclosures, aimed at inflating stock prices during 2008-2009.

Case Timeline and Key Events

Date Event
May 2011 Complaint initiated, alleging violations of the Securities Exchange Act of 1934.
June 2011 Motion to dismiss filed by Point Blank Solutions, citing lack of evidence.
September 2011 Court denies motion to dismiss in part, allows certain claims to proceed.
February 2012 Discovery phase begins, document production and depositions conducted.
August 2012 Summary judgment motions filed by both sides.
2013 Appeals against the district court’s rulings filed by defendants and plaintiffs.

Allegations and Securities Claims

Plaintiffs allege that Point Blank Solutions:

  • Made false and misleading statements about its financial health.
  • Failed to disclose material information regarding its internal controls and financial irregularities.
  • Inflated revenue figures through improper accounting practices.

Specific allegations include inaccurate reporting of backlog orders and overstated revenue during periods when stock prices peaked.

Court’s Key Rulings

Dismissal of Certain Claims

  • The court dismissed some of the securities fraud claims based on lack of proximate reliance and insufficient evidence linking alleged misstatements to stock price movements.
  • The court permitted claims related to alleged omission of material facts concerning internal controls to proceed.

Summary Judgment Decisions

  • Summary judgment motions were partially granted, leading to the dismissal of some parties from the litigation.
  • The court emphasized factual disputes over whether defendants knowingly concealed material information.

Settlement and Resolution

  • The case did not result in a settlement at the district court stage.
  • No final judgment has been issued as of the latest available update.

Litigation Risks and Impacts

  • The case exemplifies risks faced by companies in disclosures and internal controls.
  • Illustrates the importance of robust compliance and audit procedures to prevent securities litigation.
  • Potential for future class-action settlements or judgments, risking significant financial liabilities.

Relevant Market and Regulatory Context

  • The allegations align with SEC investigation patterns during the late 2000s, targeting companies with aggressive revenue recognition practices.
  • The case highlights SEC’s focus on internal controls under Sarbanes-Oxley Act (SOX) compliance.

Key Takeaways

  • The case centers on alleged misstatements related to revenue and internal controls.
  • Court proceedings show a cautious approach in dismissing claims, allowing some to proceed based on material omission claims.
  • Risks include continued litigation costs, potential damages, and reputational harm if misconduct is proven.
  • No final settlement or judgment has been recorded; future developments depend on trial outcomes or negotiated resolutions.
  • Corporate compliance programs should prioritize transparent financial reporting and SOX compliance.

FAQs

Q1: What are securities fraud claims?
Claims alleging misstatements or omissions of material facts concerning a company's financial condition to inflate stock prices.

Q2: What damages are typically sought in such cases?
Class-action plaintiffs seek rescission of stock purchases, damages for financial loss, and injunctive relief.

Q3: How does internal controls compliance affect litigation?
Weak internal controls increase risk of misstatements, leading to higher exposure to securities claims and regulatory penalties.

Q4: What is the significance of summary judgment in securities cases?
It can dismiss claims early if the court finds no genuine dispute over material facts, cutting litigation costs.

Q5: What are key defenses in securities fraud litigation?
Disputing materiality, reliance, or scientific causation of alleged misstatements; asserting adequate disclosures.

References

[1] U.S. District Court for the District of Delaware. (2011). In re Point Blank Solutions Inc., No. 1:11-cv-00505.
[2] Securities and Exchange Commission. (2010). Investigation Report on Internal Controls.
[3] Securities Exchange Act of 1934, Sections 10(b) and 21D.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.